MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze COR →
    • FindStock Picks / Stock Screener
    • Value · CORIntrinsic Value Calculator
    • Invest · CORInvestment Case
    • Hold · COR5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
COR stock logo

COR

Cencora, Inc.

$359.03
10.31
 (2.96%)
Exchange:  NYSE
Market Cap:  68.513B
Shares Outstanding:  193.178M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – DistributionView industry performance
   
CEO:  Robert Mauch
Full Time Employees:  49000
Address: 
1 West First Avenue
Conshohocken
PA
19428-1800
US
Website:  https://www.cencora.com
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
COCOR logoCORCencora, Inc.68.5B20.020.113.5%
CACAH logoCAHCardinal Health, Inc.65.0B36.226.114.3%
MCMCK logoMCKMcKesson Corporation127.3B28.228.329.3%
HSHSIC logoHSICHenry Schein, Inc.9.5B23.415.66.5%
AHAHG logoAHGAkso Health Group1.1B—0.3-1.9%
ZYZYXI logoZYXIZynex, Inc.4.1M——243.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/08/05 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue293,958,599321,332,819337,397,299
Gross Profit8,701,23810,141,52113,868,167
EBITDA3,371,4993,746,5056,116,110
Operating Income3,040,1323,647,6793,930,065
Net Income1,509,1201,554,1693,483,899

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets67,101,66776,590,11287,104,977
Total Liabilities66,314,92574,843,02783,423,737
Total Stockholders Equity645,9381,747,0853,681,240
Total Debt4,388,0767,660,77311,266,146
Cash and Cash Equivalents3,132,6484,356,1384,880,335

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow3,484,6853,875,1204,790,167
Capital Expenditure-487,173-667,981-909,501
Free Cash Flow2,997,5123,207,1393,880,666
Net Income1,519,2731,567,8143,501,421
Net Change in Cash544,9911,096,669576,940

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)394,668,617.964Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)402,441,643.179Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)398,523,250Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)8,446,272.168Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)8,630,414.751Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)8,537,588.913Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)5,432,305.461Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)5,571,799.885Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)5,501,481.078Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)8,208,111.164Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)8,369,770.470Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)8,288,277.782Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)28.350Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)28.710Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)27.990Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
293.959B  ?P/S
 (TTM)
: 
0.2
?Net Income
 (TTM)
: 
1.509B  ?P/E
 (TTM)
: 
19.96
?Enterprise Value
 (TTM)
: 
74.898B  ?EV/FCF
 (TTM)
: 
19.3
?Dividend Yield
 (TTM)
: 
0.69%  ?Payout Ratio
 (TTM)
: 
13.69%
?ROE
 (TTM)
: 
115.76%  ?ROIC
 (TTM)
: 
13.46%
?Net Debt
 (TTM)
: 
4.821B  ?Debt/Equity
 (TTM)
: 
3.06
?P/B
 (TTM)
: 
18.61  ?Current Ratio
 (TTM)
: 
0.94

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
20.07Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates COR intrinsic value between $378.83 – $506.41 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate COR Intrinsic Value

Common questions about COR valuation

Is Cencora, Inc. (COR) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Cencora, Inc. (COR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is COR a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether COR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is COR’s P/E ratio?

You can see COR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for COR?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is COR a good long-term investment?

Whether COR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Cencora, Inc.

  • Cencora, Inc. intrinsic value calculatorEstimate what the business is worth
  • Cencora, Inc. 5-year outlookWhat has to go right, and what could go wrong
COR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.96
MarketSnap

Trading Metrics:

Open: 351.12   Previous Close: 348.72
Day Low: 350.11   Day High: 359.36
Year Low: 244.82   Year High: 377.54
Price Avg 50: 326.73   Price Avg 200: 316.68
Volume: 1.359M   Average Volume: 1.336M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript
04-11-2026 13:14
Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript
Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results
04-11-2026 06:35
Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results
Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus
04-11-2026 06:35
Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
30-10-2026 10:16
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
AI Disruption May Benefit Cencora More Than Hims & Hers
14-10-2026 09:38
AI Disruption May Benefit Cencora More Than Hims & Hers
Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow
06-10-2026 03:48
Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze COR →
    • FindStock Picks / Stock Screener
    • Value · CORIntrinsic Value Calculator
    • Invest · CORInvestment Case
    • Hold · COR5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.